Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-07-03
2007-07-03
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S091100, C435S320100
Reexamination Certificate
active
10825355
ABSTRACT:
The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
REFERENCES:
patent: 5869036 (1999-02-01), Belshe et al.
patent: 58 116422 (1983-09-01), None
patent: WO 89/10405 (1989-11-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 97/34008 (1997-09-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 01/04320 (2001-01-01), None
patent: WO 01/42445 (2001-06-01), None
Breker-Klassen et al., 1996, “Comparisons of the F and HN gene sequences of different strains of bovine parainfluenza virus type 3: relationship to phenotype and pathogenicity”, Can. J. Vet. Res. 60:228-236.
Dimock and Collins, 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3”, J. Virol. 67:2772-2778.
Durbin et al., 1997, “Recovery of infectious parainfluenza virus type 3 from cDNA”, Virol. 235:323-332.
Karron et al., 1996, “Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two—to six-month-old infants”, Pediatr. Infect. Dis. J. 15:650-654.
Klippmark et al., 1990, “Antigenic variation of human and bovine parainfluenza virus type 3 strains”, J. Gen. Virol. 71:1577-1580.
Palese et al., 1996, “Negative-strand RNA viruses: genetic engineering and applications”, Proc. Natl. Acad. Sci. USA 93:11354-11358.
Shibuta et al., 1979, “Characterization of bovine parainfluenza virus type 3”, Microbiol. Immunol. 23:617-628.
Tao et al., 1999, “A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge”, Vaccine 17:1100-1108.
Tao et al., 1998, “Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1”, J. Virol. 72:2955-2961.
Karron et al., 1995, “A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children”, J. of Infect. Diseases 171: 1107-14.
Skiadopoulos et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. Mar. 1998;72(3):1762-8.
Haller, et al., (2000) “Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector”, J. Virology 74(24):11626-11635.
Schmidt et al. Journal of Virology, Oct. 2000, vol. 74, No. 19, pp. 8922-8929.
Skiadopoulos et al. Journal of Virology, Nov. 2001, vol. 75, No. 21, pp. 10498-10504.
Coelingh Kathleen L.
Haller Aurelia
MedImmune Vaccines, Inc.
Salimi Ali R.
LandOfFree
Recombinant parainfluenza virus expression systems and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant parainfluenza virus expression systems and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant parainfluenza virus expression systems and vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794634